Achieved a 100 %
approval rating from the department's senior management for court case victories deemed essential for the efficient mitigation of more than 100 life safety hazards
This recognition represents a 99 %
approval rating from employees who left reviews on Glassdoor.
In order to remain a member of the Priori network, a lawyer must receive at least a 95 %
approval rating from our clients.
With a 91 %
approval rating from our visitors and more than double the media exposure for our titles (compared to GDC and Gamescom) we are more than happy with the outcome of the event.
Powered by Unity, Ghost of a Tale looks gorgeous and it received an overwhelming amount of positive reception (95 %
approval rating from user reviews).
Despite a 99 %
approval rating from Rotten Tomatoes and opening in more than 2,000 theaters, the film didn't even earn a spot in this weekend's box office top ten.
It's the best reviewed new release, with a 79 percent «fresh»
approval rating from critics counted on Rotten Tomatoes, but a CinemaScore of C -.
People tend to really not like this film (as evidenced by a 34 %
approval rating from critics on Rotten Tomatoes and 24 % from the audience), but I really enjoyed Blackhat.
At the moment, the fifth film in the Universal franchise has a 62 percent
approval rating from critics counted on Rotten Tomatoes.
This deer call extinguisher has a 99.6 %
approval rating from the NAHC.
Mr. Cuomo garnered a 58 percent
approval rating from city voters in a Quinnipiac Poll released this week, and it seemed that Mayor Bill de Blasio's attacks on the governor weren't particular helpful — the mayor's polls are lower than ever, and New Yorkers are split when asked about their feud.
The Quinnipiac University poll out Wednesday morning shows Cuomo gets a positive job
approval rating from 46 percent of voters statewide.
Mayor Bloomberg achieves his highest
approval rating from city voters: Mayor Michael Bloomberg's job approval rating, his combined excellent and good scores, is 58 %, the highest point he's attained during his tenure in City Hall.
There are a few more interesting findings in them — David Cameron's initial net
approval rating from YouGov is +34 — that the third highest approval rating I can find for any Tory leader ever (the top two being John Major's approval ratings during the Gulf War).
The latest Siena College poll shows that Cuomo had a 68 percent
approval rating from liberals — which the Cuomo insider said is evidence that shoots down claims that the governor has a problem with the party's leftist grassroots.
Rallying against the bill included groups like Citizen Action, which have sought to further push Cuomo to the left on a variety of issues (Cuomo continues to enjoy a strong
approval rating from self - identified liberals, even as advocates have faulted him for not doing enough).
The app has a 4 +
approval rating from the Apple app store, and the organization is quick to point out that this rating is reserved for those apps that «contain no objectionable material.»
In all seriousness, these muffins got high
approval ratings from friends, family, and coworkers, all of whom were surprised that these were both vegan and gluten - free!
Ian adds that initial customer workshops for Ishida Expert have proved successful with very positive feedback and high
approval ratings from users.
District food directors won't even consider dishes that score lower than 80 percent
approval ratings from student tasting panels.
But, Mario Cuomo enjoyed 71 % and 64 %
approval ratings from New Yorkers when he launched his successful re-election bids in 1986 and 1990, respectively.
That is why it has high
approval ratings from Tory voters, and much lower ones even from that half of the LibDem vote which is sticking with them.
If a school district decides to pierce the tax cap, it must get a 60 percent
approval rate from voters.
Despite the Garner case, Mayor Bill de Blasio's approval ratings have held steady at 50 percent, virtually unchanged since June, with continued overwhelming
approval ratings from black voters at 65 percent.
Until recently, Cuomo enjoyed sky high
approval ratings from nearly all New Yorkers, in the 70 % range.
The Bitcoin Core team presented a scaling proposal that needed a 95 %
approval rate from the miner community, called SegWit (Segregated Witnesses).
I am pleased to share that the MCE program continues to receive high
approval ratings from registrants.
Not exact matches
Important factors that could cause actual results to differ materially
from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build
rates of certain aircraft; 6) the effect on aircraft demand and build
rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange
rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory
approvals, including our ability to obtain in a timely fashion any required regulatory or other third party
approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting
from cancellations, deferrals, or reduced orders by their customers or
from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations
from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover
from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount
rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition
from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit
ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest
rates increase substantially; 27) the effectiveness of any interest
rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange
rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.
These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition
from generic drug manufacturers; data
from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory
approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment
rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded
from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.
Second,
approval rates by the U.S. Food and Drug Administration have steadily risen over the past two decades, climbing
from 23 percent in 1994 to 89 percent and 77 percent in 2014 and 2015, respectively.
Such risks, uncertainties and other factors include, without limitation: (1) the effect of economic conditions in the industries and markets in which United Technologies and Rockwell Collins operate in the U.S. and globally and any changes therein, including financial market conditions, fluctuations in commodity prices, interest
rates and foreign currency exchange
rates, levels of end market demand in construction and in both the commercial and defense segments of the aerospace industry, levels of air travel, financial condition of commercial airlines, the impact of weather conditions and natural disasters and the financial condition of our customers and suppliers; (2) challenges in the development, production, delivery, support, performance and realization of the anticipated benefits of advanced technologies and new products and services; (3) the scope, nature, impact or timing of acquisition and divestiture or restructuring activity, including the pending acquisition of Rockwell Collins, including among other things integration of acquired businesses into United Technologies» existing businesses and realization of synergies and opportunities for growth and innovation; (4) future timing and levels of indebtedness, including indebtedness expected to be incurred by United Technologies in connection with the pending Rockwell Collins acquisition, and capital spending and research and development spending, including in connection with the pending Rockwell Collins acquisition; (5) future availability of credit and factors that may affect such availability, including credit market conditions and our capital structure; (6) the timing and scope of future repurchases of United Technologies» common stock, which may be suspended at any time due to various factors, including market conditions and the level of other investing activities and uses of cash, including in connection with the proposed acquisition of Rockwell; (7) delays and disruption in delivery of materials and services
from suppliers; (8) company and customer - directed cost reduction efforts and restructuring costs and savings and other consequences thereof; (9) new business and investment opportunities; (10) our ability to realize the intended benefits of organizational changes; (11) the anticipated benefits of diversification and balance of operations across product lines, regions and industries; (12) the outcome of legal proceedings, investigations and other contingencies; (13) pension plan assumptions and future contributions; (14) the impact of the negotiation of collective bargaining agreements and labor disputes; (15) the effect of changes in political conditions in the U.S. and other countries in which United Technologies and Rockwell Collins operate, including the effect of changes in U.S. trade policies or the U.K.'s pending withdrawal
from the EU, on general market conditions, global trade policies and currency exchange
rates in the near term and beyond; (16) the effect of changes in tax (including U.S. tax reform enacted on December 22, 2017, which is commonly referred to as the Tax Cuts and Jobs Act of 2017), environmental, regulatory (including among other things import / export) and other laws and regulations in the U.S. and other countries in which United Technologies and Rockwell Collins operate; (17) the ability of United Technologies and Rockwell Collins to receive the required regulatory
approvals (and the risk that such
approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the merger) and to satisfy the other conditions to the closing of the pending acquisition on a timely basis or at all; (18) the occurrence of events that may give rise to a right of one or both of United Technologies or Rockwell Collins to terminate the merger agreement, including in circumstances that might require Rockwell Collins to pay a termination fee of $ 695 million to United Technologies or $ 50 million of expense reimbursement; (19) negative effects of the announcement or the completion of the merger on the market price of United Technologies» and / or Rockwell Collins» common stock and / or on their respective financial performance; (20) risks related to Rockwell Collins and United Technologies being restricted in their operation of their businesses while the merger agreement is in effect; (21) risks relating to the value of the United Technologies» shares to be issued in connection with the pending Rockwell acquisition, significant merger costs and / or unknown liabilities; (22) risks associated with third party contracts containing consent and / or other provisions that may be triggered by the Rockwell merger agreement; (23) risks associated with merger - related litigation or appraisal proceedings; and (24) the ability of United Technologies and Rockwell Collins, or the combined company, to retain and hire key personnel.
One other tidbit
from the Glassdoor study: Uber co-founder Travis Kalanick, who stepped down
from his post as CEO under intense pressure on Wednesday, had an above - average 77 %
approval rating.
In fact, the average CEO
approval rating is 67 % — a far cry
from Dorer's 99 % and Cook's 93 %
approval rating.
The fundraising numbers help explain why more Republicans — particularly those facing re-election next year — aren't openly distancing themselves
from a president whose
approval rating hovers below 40 percent and whose White House has been wracked by public back - biting and legislative stumbles.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results
from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory
approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data
from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange
rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified
from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Factors that could cause actual results to differ include general business and economic conditions and the state of the solar industry; governmental support for the deployment of solar power; future available supplies of high - purity silicon; demand for end - use products by consumers and inventory levels of such products in the supply chain; changes in demand
from significant customers; changes in demand
from major markets such as Japan, the U.S., India and China; changes in customer order patterns; changes in product mix; capacity utilization; level of competition; pricing pressure and declines in average selling prices; delays in new product introduction; delays in utility - scale project
approval process; delays in utility - scale project construction; delays in the completion of project sales; continued success in technological innovations and delivery of products with the features customers demand; shortage in supply of materials or capacity requirements; availability of financing; exchange
rate fluctuations; litigation and other risks as described in the Company's SEC filings, including its annual report on Form 20 - F filed on April 27, 2017.
Factors that could cause actual results to differ include general business and economic conditions and the state of the solar industry; governmental support for the deployment of solar power; future available supplies of high - purity silicon; demand for end - use products by consumers and inventory levels of such products in the supply chain; changes in demand
from significant customers; changes in demand
from major markets such as Japan, the U.S., India and China; changes in customer order patterns; changes in product mix; capacity utilization; level of competition; pricing pressure and declines in average selling prices; delays in new product introduction; delays in utility - scale project
approval process; delays in utility - scale project construction; continued success in technological innovations and delivery of products with the features customers demand; shortage in supply of materials or capacity requirements; availability of financing; exchange
rate fluctuations; litigation and other risks as described in the Company's SEC filings, including its annual report on Form 20 - F filed on April 20, 2016.
Factors that could cause actual results to differ include general business and economic conditions and the state of the solar industry; governmental support for the deployment of solar power; future available supplies of high - purity silicon; demand for end - use products by consumers and inventory levels of such products in the supply chain; changes in demand
from significant customers; changes in demand
from major markets such as Japan, the U.S., India and China; changes in customer order patterns; changes in product mix; capacity utilization; level of competition; pricing pressure and declines in average selling prices; delays in new product introduction; delays in utility - scale project
approval process; delays in utility - scale project construction; cancelation of utility - scale feed - in - tariff contracts in Japan; continued success in technological innovations and delivery of products with the features customers demand; shortage in supply of materials or capacity requirements; availability of financing; exchange
rate fluctuations; litigation and other risks as described in the Company's SEC filings, including its annual report on Form 20 - F filed on April 27, 2017.
Florida Republican Marco Rubio's
approval rating dropped 5 points
from November, down to 45 percent.
Small business loan
approval rates at big banks ($ 10 billion + in assets) rose to 20 % in June
from 19.6 % in May, while
approval rates at small banks slipped to 51.4 %
from to 51.6 % last month.
Sanders maintained his spot at the top of the list
from November, with an 80 percent
approval rating.
West Long Branch, NJ - Donald Trump's current job
approval rating is the lowest registered in the Monmouth University Poll since he took office, with the biggest drop coming
from independent women.
In June, loan
approval rates at credit unions improved slightly to 43.7 %
from 43.6 % in May, while
approval rates by alternative lenders slipped for the fifth consecutive month to 63.2 % in June,
from 63.3 % in May «Entrepreneurs are getting funding
from banks at attractive interest
rates.
She faces significant pressure
from a newly elected Hollande, a political leader in Monti whose
approval ratings are plummeting at home and needs to show some form of success on the European state, and a leader in Rajoy whose management of his country's banking crisis has been widely criticized.
In March, 40 % of people in Michigan, Ohio, Indiana, Illinois and Pennsylvania voiced
approval for the president's handling of trade, down
from 45 % in January 2018 and the 49 %
approval rating he enjoyed a year ago.
As was explained in «Box C» in the February 2004 Statement, the level of loan
approvals is a leading indicator of the growth
rate of credit, though the relationship
from month to month is not very precise.
Previously unpublished questions
from the same poll conducted by Marc Henry «s ThinkHQ and provided to daveberta.ca showed Edmonton mayor Don Iveson and Calgary mayor Naheed Nenshi with 70 % and 71 %
approval ratings.
This widening in the gap between fixed and variable housing
rates is likely to have contributed to the pick - up in the proportion of borrowers choosing to take out fixed -
rate housing loans: in November 2004, the latest available data, 11 per cent of new owner - occupier housing loan
approvals were at fixed
rates, up
from 7 per cent three months earlier and the highest share since the beginning of 2004, which followed a period of monetary policy tightening (Graph 45).
Following the vote, Credit Suisse's Alethia Young maintained an Outperform
rating on Puma's stock with a price target boosted
from $ 58 to $ 90, although the company's announcement doesn't yet imply the
approval of neratinib.
Vladimir Putin's
approval rating, which has fluctuated between 80 % and 90 % since the start of Russia's meddling in Ukraine, could suffer, since apart
from belligerent foreign adventures, the other thing that his popularity has historically depended on is rising standards of living for the population.